DECLARATION OF CONFLICT OF INTEREST
|
|
- Meryl Perkins
- 5 years ago
- Views:
Transcription
1 DECLARATION OF CONFLICT OF INTEREST
2 Risk Stratification in Antithrombotic Management: Is There Room for Improvement? August 28, 2011 Elaine M. Hylek, MD, MPH Boston University
3 DISCLOSURE INFORMATION Research: NIH/NINDS, NIH/NHLBI Executive Steering Committee ARISTOTLE trial- Sponsors-BMS and Pfizer; Executive Steering Committee ORBIT-AF Registry- Sponsor-Johnson & Johnson, Ortho-McNeil Advisory Boards: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Ortho-McNeil, Merck, Pfizer Lecture Honorarium: Bayer, Boehringer Ingelheim
4
5 Stanford Stroke Center, Albers G.
6 TEE depicting a large LAA thrombus attached to the lateral wall Hesse, B. et al. Circulation 2006;113:e e
7 Efficacy of Warfarin in Atrial Fibrillation Five Randomized Trials in Non-Rheumatic AF Study Warfarin (#) Cont. (#) INR RR p-value AFASAK % SPAF % 0.01 BAATAF % <0.05 CAFA* % 0.25 SPINAF % *Stopped early due to published positive results 68% overall risk reduction for stroke
8 Hazards of Anticoagulant Medications #1 in 2003 and 2004 in the number of mentions of deaths for drugs causing adverse effects in therapeutic use 1 Warfarin-6% of 702,000 ADEs treated in ED per year; 17% require hospitalization 1 21 million warfarin prescriptions in 1998>>>31 million in The incidence AC-related intracranial hemorrhage quintupled during this time period 3 1 Wysowski DK, et al. Arch Intern Med. 2007;167: Budnitz DS, et al. JAMA. 2006;296: Flaherty ML, et al. Neurology. 2007;68:
9 Optimizing Benefit and Reducing Risk Hemorrhage Thrombosis AF stroke associated with a 30-day mortality of 24%.
10 Validation of Clinical Classification Schemes for Predicting Stroke Results From the National Registry of Atrial Fibrillation CHADS 2 Score Points Congestive heart failure = 1 Hypertension = 1 Age 75 years of age = 1 Diabetes = 1 Prior stroke/tia/systemic embolus = 2 82 y.o. male with HTN and prior stroke (CHADS 2 Score = 4) Gage B, et. al. JAMA. 2001;285:
11 Estimated Stroke Risk by CHADS 2 Score CHADS 2 Score Adjusted Stroke Rate (%/y) (1.2 to 3.0) (2.0 to 3.8) (3.1 to 5.1) (4.6 to 7.3) (6.3 to 11.1) (8.2 to 17.5) (10.5 to 27.4) Gage B, et al. JAMA 2001; 285:
12 Risk Categorization, Incidence of TE* and Predictive Ability for Risk Schema among the Euro Heart Survey Patients Categorization of TE Risk (% in risk category) Predictive ability Low Intermediate High c-statistic AFI SPAF CHADS 2 -revised Framingham ACCP *Ischemic *Ischemic stroke, stroke, pulmonary pulmonary embolism embolism or peripheral or peripheral embolism embolism Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Chest 2010
13 Stroke in AF Working Group Systematic review: 4 consistent independent risk factors for stroke: hypertension, age, diabetes, prior stroke/tia For patients with AF who have 1 or more of the following less well-validated risk factors either aspirin or a vitamin K antagonist is reasonable for prevention of TE: age 65 to 74 y, female gender, or CAD. Neurology 2007;69: Circulation 2006; August. Neurology 2007;69:546-54
14 CHA 2 DS 2 -VASc Congestive heart failure/lv dysfunction =1 Hypertension =1 Age 75 =2 Diabetes mellitus =1 Stroke/TIA/TE =2 Vascular disease (MI, PAD, aortic plaque) =1 Age =1 Sex category (Female gender) =1 0=low risk; 1=intermediate risk; 1=high risk Lip GYH, et al. Chest 2010;137:263-72
15 Risk Categorization, Incidence of TE* and Predictive Ability for Risk Schema among the Euro Heart Survey Patients Categorization of TE Risk (% in risk category) Predictive ability Low Intermediate High c-statistic AFI SPAF CHADS 2 -revised Framingham ACCP CHA 2 DS 2 -VASc *Ischemic stroke, pulmonary embolism or peripheral embolism Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Chest 2010
16 Risk Categorization, Incidence of TE and Predictive Ability for Risk Schema among the Euro Heart Survey Patients CHA 2 DS 2 -VASc Low Risk 0% CHADS 2 Low Risk 1.4% SPAF Low Risk 1.8% Intermediate Risk 0.6% vs 3% Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Chest 2010
17
18 Wyse G, Gersh B. Circulation.
19 1. Obesity What about other Touted Risk Factors for Stroke in AF? 2. Inflammation 3. Renal dysfunction 4. Genetics 5. Echocardiography-LAA anatomy, LAA emptying velocity 6. Endothelial dysfunction-vwf 7. D-dimer, markers of platelet activation, tissue factor (TF) induction in mononuclear cells (MNCs) and granulocytes 8. New onset AF
20 Age- and sex-adjusted hazards of progression from paroxysmal to permanent AF by BMI Tsang T S et al. Eur Heart J 2008;29: Published on behalf of the European Society of Cardiology. All rights reserved. The Author For permissions please journals.permissions@oxfordjournals.org
21 Touted Pathogenetic Mechanisms Linking Obesity to Risk of AF Correlation with hypertension, heart failure, diabetes mellitus, metabolic syndrome Left atrial diameter Obstructive sleep apnea Epicardial/pericardial fat-secretion of adipokines:? role of inflammation (IL-6, TNFα, CRP) on cardiac contractile and vascular dysfunction
22 Epicardial and Perivascular Fat Ouwens DM, et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med Aug 16. Thanassoulis G, et al. Pericardial fat is associated with prevalent atrial fibrillation. Circ Arrhythm Electrophysiol Aug 1;3. Batal O, et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol Aug 1;3.? local effect of adipose tissue perhaps mediated by secretion of cytokines??? atrial tissue
23 ? Role of Inflammation Bruins P, et al. Circulation. 1997;96: Noted that levels of IL-6 rose sharply and peaked within 6 hours of cardiac surgery. CRP peaked on second post-op day CRP-complement complexes peaked 2 nd to 3 rd post-operative day Atrial arrhythmias also peak within 2-3 days
24 Role of Inflammatory Cells (Nat Med 2010) Neutrophil Azurophilic primary granules contain myeloperoxidase (MPO). MPO is released by activated neutrophils generating HOCl. MPO also generates reactive nitrogen intermediates (NOx) deleterious to endothelium.
25 Myeloperoxidase Deficient Mice (mpo / ) Wild Type (control): MPO Knockout: Marked decrease in atrial fibrosis, reduced matrix metalloproteinase activity, and decreased susceptibility to AF. Rudolph V. Nat Med April ; 16(4):
26 Inflammatory Infiltrate in Atrium Activated Neutrophils Myeloperoxidase HOCl + Reactive Nitrogen Intermediates Endothelial damage, MMP, Fibrosis Tissue conducive to AF
27 Association of left atrial fibrosis detected by delayedenhancement MRI and risk of stroke in patients with atrial fibrillation Daccarett M, et al. JACC 2011 Feb 15;57(7):831-8
28 Ramoni R, et al. Stroke 2009;40 Ramoni R, et al. Stroke 2009;40 STROKE GENOMICS
29 Challenges for Further Refinement of Risk Prediction Tools Universal application Practical Cost Clinical endpoints and incremental benefit? Applicable to all AF types: Inheritable AF, Focal, Complex, Post-operative AF [Pathophysiological classification for AF type: Kirchhof P, Lip GYH, et al. 3 rd AF Competence NETwork/EHRA consensus conference. Europace Jul 26]
30
31 Cumulative Incidence of Major Bleeding in the First Year Among Patients Newly Starting Warfarin by Age Days on Warfarin Age <80 Age >=80 Hylek EM et al, Circulation 2007;115(21): Hylek EM et al, Circulation 2007;115(21):
32 Age and Gastrointestinal Hemorrhage THE FACTS: Incidence of UGIB and LGIB increase with age. 70% of acute UGIB occur > 60 years of age. Incidence of LGIB increases 200-fold from the 3 rd to 9 th decade of life..
33 46% mortality 17% major deficit 2/3 occur with an INR in range OR 80 years of age 2.8 (1.3 to 5.8) p<0.001 Hylek EM, Singer DE. Ann Intern Med 1994
34 Risk of Stopping Therapy in the First Year Among Patients Newly Starting Warfarin by Age Days on Warfarin Age <80 Age >=80 Hylek EM et al, Circulation 2007;115(21):
35 Risk Stratification for Major Hemorrhage HASBLED Score Points Hypertension (SBP >160mmHG) = 1 Abnormal renal or liver fxn = 1 or 2 Stroke = 1 Bleeding tendency = 1 Labile INRs (if on warfarin) = 1 Elderly (e.g. age >65 ) = 1 Drugs (e.g. NSAIDs, aspirin) or = 1 or 2 alcohol abuse Lip, GYH, et al. (J Am Coll Cardiol 2011;57:000 00)
36 How Would you Use this Information? Address modifiable risk factors Follow high risk patients more closely Reinforce early warning signs of bleeding Reconsider risk/benefit for those patients with high bleeding risk and low risk of stroke
37 CONCLUSION Our current risk stratification tools for ischemic stroke work modestly well. Incorporation of biomarkers, genomics, radiologic imaging will be challenged by cost, availability, and their added incremental value. Ris k factors for stroke overlap significantly with risk factors for hemorrhage making it difficult to discriminate risk in clinical practice. Risk of both ischemic stroke and major hemorrhage increase with increasing number of risk factors. More research is needed to better refine risk, explore temporal associations with risk, determine applicability to different AF types.
Controversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationThromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationRisk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers
Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationControversies in Risk Stratification
Controversies in Risk Stratification There are more questions than answers So---Let me pose the questions Banff 2016 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of
More informationObjectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application
Falling Down on Warfarin Therapy David Andrew Jacob, PharmD Pharmacy Resident 2013-2014 Dayton VA Medical Center Dayton, Ohio Objectives Describe CHADS 2 score and the decision to anticoagulate patients
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationDOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017
DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017 Disclosures for David Garcia Consultancy: Boehringer Ingelheim; Bristol-Meyers Squibb; Daiichi
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationExclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationAnti-Thrombotic Therapy Update 2017 Sophia-Antipolis (France), February European Heart House
Anti-Thrombotic Therapy Update 2017 Sophia-Antipolis (France), February 23-25 2017 European Heart House SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY Understanding Thrombosis in... February 23 2017 14:10-15:45
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationNew Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS,
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationThe HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study
The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study Apostolakis S 1, Lane DA 1, Buller H 2, Lip GY 1 1 University
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationHAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest
HAS-BLED Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest r.pisters@mumc.nl Background major bleeding risk High stroke risk frequently warrants use of oral anticoagulation
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationIncreased Levels of D-dimer in Atrial Fibrillation Identify Patients With Higher Risk of Thromboembolic Events and Death
Increased Levels of D-dimer in Atrial Fibrillation Identify Patients With Higher Risk of Thromboembolic Events and Death Christina Christersson, Malin Schollin, John H. Alexander, Bernand J. Gersh, John
More informationTREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS. Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai
TREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai Acknowledgement Many of the slides for this presentation were obtained
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationCurrent state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More informationAF Stroke Prevention Through Screening, Intervention and Patient Choice
AF Stroke Prevention Through Screening, Intervention and Patient Choice Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GP Partner Westcliffe Medical Group Trustee AF Association Trustee
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationPapel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico
Imagiologia na Fibrilhac ão Auricular Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Mª João Andrade Diagnosis and timely detection of atrial fibrillation Echo-machines
More informationRefining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
CHEST Original Research Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices Faculty John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical University
More informationV. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip
PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationConsequences of stroke and AF
Consequences of stroke and AF Lorenzo G Mantovani Center of Pharmacoeconomics University of Naples Center for Public Health Research University of Milan Bicocca Questions Is stroke frequent? Is stroke
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationMEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME MONITORING DEVICE. POLICY NUMBER: CATEGORY: Equipment/Supplies
MEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME 06/23/16, 6/22/17 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationLa chiusura dell auricola per la prevenzione dello stroke nel paziente con FA
Antonio Manari U.O. Cardiologia Interventistica Azienda Ospedaliera Santa Maria Nuova Reggio Emilia Istituto di Ricovero e Cura a Carattere Scientifico La chiusura dell auricola per la prevenzione dello
More informationManagement of atrial fibrillation in diabetes
Stephen Dobbin 1 MBChB, MRCP, Cardiology SpR Miles Fisher 2 MD, FRCP, Consultant Physician Gerry McKay 2 BSc (Hons), FRCP, Consultant Physician 1 Department of Cardiology, Golden Jubilee National Hospital,
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationESC. Update of the ESC Guidelines on Medical Therapy. John Camm. ICM Internationales Congress Center München
ESC 2012 ICM Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy
More informationA COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)
A COhort of antithrombotic use and Optimal INR Level in patients with nonvalvular atrial fibrillation in Thailand (COOL AF Thailand) Prevalence of Atrial Fibrillation Number of AF Patients Predicted to
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationMEDLINE for studies published through March 11, 2015, that reported on AF and stroke, bleeding risk factors, and stroke prevention.
Clinical Review & Education Review A Systematic Review Gregory Y. H. Lip, MD; Deirdre A. Lane, PhD IMPORTANCE Atrial fibrillation (AF) is associated with an increase in mortality and morbidity, with a
More informationwww.stopastroke.co.uk Acknowledgements Rachel Rayment Graham Shortland Tristan Groves Sarah Holroyd Shakeel Ahmad Steve Gage Darrell Baker Fiona Walker Clare Evans Marilyn Rees Kay Jeynes Peter O Callaghan
More informationAssise de l AMCAR : 27Avril Anticoagulant treatment of AF
Assise de l AMCAR : 27Avril 2017 Cardiovascular morbidity and mortality and AF The Five Domains of Integrated AF Management FA: pathophysiology of thrombus formation Alteration of the atrial wall Myocytic
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationUpdate in Outpatient Medicine ACP Scientific Session November 12, 2016
Update in Outpatient Medicine ACP Scientific Session November 12, 2016 Robert Gluckman MD, MACP Chief Medical Officer Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers
More information